Werewolf Therapeutics provided a business update, announcing progress in their clinical trials for WTX-124, a conditionally activated therapeutic for cutaneous melanoma, with full enrollment in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果